Molecular Instruments announced the availability of its HCR Pro RNA in situ hybridization assay on the Leica BOND-III automated staining platform, introducing a fully ambient-temperature, protease-free RNA-ISH workflow for routine clinical and translational pathology use. The disclosure places the company’s hybridization chain reaction technology directly into high-throughput, regulated laboratory environments where consistency, tissue preservation, and automation reliability are increasingly non-negotiable.

What matters most about this launch is not incremental compatibility with another autostainer, but the implicit challenge it poses to how RNA in situ assays have historically been engineered for clinical scale. RNA-ISH has long been positioned as analytically powerful but operationally fragile, dependent on elevated temperatures, enzymatic digestion, and tightly tuned protocols that perform well in expert hands yet degrade under real-world automation pressures. By removing heat and protease steps entirely, Molecular Instruments is signaling that RNA-ISH may no longer need to trade robustness for sensitivity in routine diagnostic workflows.

Why ambient-temperature RNA-ISH fundamentally alters the risk profile of automated pathology workflows

Temperature control remains one of the least visible but most consequential variables in automated staining systems. In high-volume pathology laboratories, subtle thermal gradients across slide decks, reagent reservoirs, or instrument decks can introduce slide-to-slide variability that is difficult to detect until downstream interpretation fails. Industry observers note that these issues are magnified in RNA-based assays, where nucleic acid stability and hybridization kinetics are especially sensitive to heat.

By operating entirely at ambient temperature, HCR Pro effectively removes a class of failure modes that laboratories have historically compensated for through tighter QC, repeat testing, or conservative assay deployment. This matters because most labs do not evaluate RNA-ISH assays based on peak performance under ideal conditions, but on worst-case reproducibility across long runs, mixed tissue types, and varying operator experience. An assay that is less sensitive to environmental drift becomes easier to standardize, easier to validate, and ultimately easier to defend in regulated settings.

The elimination of protease digestion introduces a second structural change. Protease treatment has long been accepted as a necessary compromise to enable probe access, but it also introduces variability tied to tissue fixation quality, sample age, and operator timing. Clinicians tracking RNA pathology adoption increasingly view tissue preservation not as a cosmetic benefit, but as a prerequisite for multiplexed workflows where RNA, protein, and morphology must coexist on the same slide. Protease-free chemistry reduces the likelihood that RNA detection degrades downstream immunohistochemistry or immunofluorescence readouts, a constraint that has limited broader RNA-ISH deployment outside specialized assays.

How HCR Pro reframes sensitivity versus robustness tradeoffs compared with conventional RNA-ISH platforms

Traditional RNA-ISH methods have optimized sensitivity through enzymatic amplification and thermal stringency, often at the expense of workflow resilience. Hybridization chain reaction approaches invert that logic by relying on programmable nucleic acid self-assembly rather than enzymes to generate signal amplification. Industry observers note that this design choice becomes particularly relevant in automated systems, where enzyme performance can drift due to temperature variation, reagent aging, or subtle protocol deviations.

HCR Pro’s clinical positioning suggests that Molecular Instruments believes signal-to-background performance no longer needs to be traded off against operational simplicity. The claim is not that ambient-temperature workflows outperform all heated protocols in absolute sensitivity, but that they deliver sufficient sensitivity with far fewer hidden variables. In a clinical context, that distinction matters more than academic peak performance. Pathologists and lab directors prioritize interpretability, consistency, and confidence across patient samples rather than marginal gains that require narrow operating windows.

The ability to visualize low-abundance targets without aggressive tissue disruption also carries implications for biomarker discovery and translational research. As RNA-based biomarkers move closer to clinical decision-making, the tolerance for assays that consume limited tissue or require repeat sections declines sharply. An RNA-ISH platform that preserves morphology and antigenicity while delivering readable signal positions itself as a companion rather than a competitor to established protein-based assays.

What compatibility with Leica BOND-III reveals about Molecular Instruments’ clinical ambitions

The Leica BOND-III platform occupies a distinctive position in pathology automation. It is widely installed, deeply embedded in clinical laboratories, and often standardized across hospital networks. Integration without software modifications lowers the operational barrier for adoption and reduces validation complexity, which is often a decisive factor in whether new assays move beyond pilot use.

Regulatory watchers suggest that aligning with an entrenched automation platform is a strategic step toward normalization rather than novelty. RNA-ISH technologies have historically been viewed as add-on tools requiring specialized instrumentation or expertise. Running HCR Pro on the same platform used for routine immunohistochemistry reframes RNA detection as an extension of standard practice rather than a parallel workflow.

This positioning also hints at a longer-term commercial strategy. Clinical-grade RNA assays face slower uptake not because of analytical skepticism, but because of friction at the interface of workflow, staffing, and compliance. By embedding into existing infrastructure, Molecular Instruments reduces the burden on labs to justify RNA-ISH as a special case. That shift may prove more important than incremental performance gains in determining long-term adoption curves.

Clinical relevance and limitations that laboratories will scrutinize during early deployment

Despite the appeal of ambient-temperature operation, laboratories will closely examine how HCR Pro performs across diverse FFPE samples, including older archival tissues and specimens with variable fixation quality. Protease-free protocols reduce one source of variability but may introduce others related to probe penetration or target accessibility in heavily cross-linked samples. Early adopters will likely test the platform across a spectrum of tissue types before expanding use.

Interpretation consistency will also remain under scrutiny. RNA-ISH signals, particularly for low-abundance targets, must be distinguishable not only from background but from biological heterogeneity. Pathologists evaluating clinical readiness will look for clear signal morphology that integrates seamlessly into existing diagnostic frameworks rather than requiring retraining or reinterpretation.

Another open question is throughput under real-world conditions. While ambient-temperature workflows reduce thermal constraints, they must still meet turnaround expectations in high-volume labs. Industry observers will watch closely whether HCR Pro protocols maintain run times comparable to conventional automated staining or introduce bottlenecks that limit scalability.

What this launch signals for the future of RNA-based diagnostics in routine pathology

The broader implication of Molecular Instruments’ announcement is that RNA-ISH is being repositioned from a specialized molecular technique to an operationally mature diagnostic modality. This shift aligns with growing interest in RNA biomarkers that capture transcriptional states not visible at the protein level, particularly in oncology and inflammatory disease.

Clinicians tracking the field believe that the next phase of RNA diagnostics will depend less on discovering new targets and more on making RNA detection operationally invisible. Assays that behave like immunohistochemistry in terms of reliability and workflow fit are more likely to achieve sustained clinical use. Ambient-temperature, protease-free RNA-ISH moves the field closer to that threshold.

However, adoption will depend on more than chemistry. Reimbursement frameworks, clinical utility evidence, and standardization across institutions will ultimately determine whether RNA-ISH becomes routine or remains adjunctive. Molecular Instruments’ approach addresses one major barrier, but others remain unresolved.

What industry observers will watch next as clinical RNA-ISH moves toward standardization

Following this launch, attention will likely shift to validation data emerging from early clinical adopters and translational programs. Evidence that HCR Pro can support multi-analyte workflows without compromising tissue integrity will be particularly influential. Regulators and accreditation bodies will also monitor how ambient-temperature RNA-ISH is incorporated into quality management systems and whether it simplifies or complicates compliance.

Competitor response will be another indicator. If ambient-temperature operation proves to materially reduce failure rates or repeat testing, pressure will mount on other RNA-ISH platforms to revisit their reliance on heat and enzymatic digestion. This could accelerate a broader redesign of RNA diagnostics toward robustness-first architectures.

In that sense, Molecular Instruments’ move is less about a single assay launch and more about redefining what clinical-grade RNA detection is expected to tolerate. If successful, it may narrow the gap between molecular insight and practical deployment that has constrained RNA pathology for more than a decade.

  clinical pathology, FFPE tissue, HCR Pro RNA-ISH, Leica BOND-III, molecular diagnostics, Molecular Instruments, RNA in situ hybridization, translational pathology